Nvwm LLC Acquires Shares of 984 argenx SE (NASDAQ:ARGX)

Nvwm LLC purchased a new position in shares of argenx SE (NASDAQ:ARGX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 984 shares of the company's stock, valued at approximately $533,000.

Several other institutional investors also recently modified their holdings of the stock. Profund Advisors LLC increased its holdings in argenx by 3.0% in the second quarter. Profund Advisors LLC now owns 973 shares of the company's stock valued at $418,000 after purchasing an additional 28 shares during the period. Wealth Alliance increased its holdings in argenx by 4.8% in the second quarter. Wealth Alliance now owns 628 shares of the company's stock valued at $270,000 after purchasing an additional 29 shares during the period. GAMMA Investing LLC increased its holdings in argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company's stock valued at $51,000 after purchasing an additional 40 shares during the period. Toronto Dominion Bank increased its holdings in argenx by 16.5% in the first quarter. Toronto Dominion Bank now owns 303 shares of the company's stock valued at $119,000 after purchasing an additional 43 shares during the period. Finally, Sequoia Financial Advisors LLC increased its holdings in argenx by 3.1% in the second quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company's stock valued at $737,000 after purchasing an additional 52 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Trading Down 1.2 %

NASDAQ ARGX traded down $6.91 during trading hours on Monday, hitting $588.67. The company's stock had a trading volume of 264,569 shares, compared to its average volume of 309,067. argenx SE has a 52 week low of $327.73 and a 52 week high of $610.73. The company has a market capitalization of $35.20 billion, a PE ratio of -668.94 and a beta of 0.61. The company's 50-day simple moving average is $539.46 and its two-hundred day simple moving average is $467.19.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 0.96%. The business had revenue of $588.88 million for the quarter, compared to analysts' expectations of $543.29 million. During the same quarter last year, the firm earned ($1.25) EPS. Research analysts anticipate that argenx SE will post -0.36 EPS for the current fiscal year.

Analyst Ratings Changes

ARGX has been the subject of a number of recent research reports. Wedbush increased their price objective on argenx from $519.00 to $560.00 and gave the company an "outperform" rating in a report on Friday, July 26th. Raymond James restated a "strong-buy" rating and issued a $605.00 price objective on shares of argenx in a report on Thursday, October 10th. JMP Securities increased their price target on argenx from $497.00 to $606.00 and gave the stock a "market outperform" rating in a report on Friday. Oppenheimer increased their price target on argenx from $560.00 to $646.00 and gave the stock an "outperform" rating in a report on Friday. Finally, William Blair upgraded argenx from a "market perform" rating to an "outperform" rating in a report on Friday. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $598.44.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.